

1869

## Tacrolimus: A Potential New Treatment for Autoimmune Chronic Active Hepatitis: Results of an Open-Label Preliminary Trial

David H. Van Thiel, M.D., Harlan Wright, M.D., Patricia Carroll, M.D., Kareem Abu-Elmagd, M.D., Horacio Rodriguez-Rilo, M.D., John McMichael, B.Sc., William Irish, M.Sc., and Thomas E. Starzl, M.D., Ph.D.  
*Pittsburgh Transplantation Institute, Section of Transplantation Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania*

Autoimmune chronic active hepatitis (CAH-A) is a chronic liver disease of unknown etiology that is believed to have an autoimmune pathogenesis. The disease is slowly progressive until hepatic failure and portal hypertension develop and either death or liver transplantation occur. Currently, the only widely recognized therapy is the administration of glucocorticoids, which have both anti-inflammatory and immunosuppressive actions. Many patients cannot tolerate such therapy because of the psychiatric, osteoporotic, and weight-enhancing actions of steroids. Tacrolimus (FK 506) is a new macrolide antibiotic that has an immunosuppressive activity that is estimated to be 10–200 times greater than that of cyclosporine. Because of its greater immunosuppressive activity, we have used it in the treatment of 21 patients with autoimmune chronic active hepatitis. Before each subject was treated, a liver biopsy and a panel of hematological, serological, and biochemical parameters were assessed. The Tacrolimus was administered orally at 12-h intervals, and the dose was controlled by monitoring plasma FK trough levels. After 3 months of therapy at an oral dose of 3 mg twice a day, having achieved a median blood level of 0.5 ng/ml, the serum ALT level was reduced by 80%, and the AST level was reduced by 70%. Modest change in the white blood cell count and platelet count were noted. The median BUN level increased from a level of 12 to 18 mg/dl, and the serum creatinine increased from 0.9 to 1.3 mg/dl. These preliminary data demonstrate that: 1) Tacrolimus can be used to successfully treat CAH-A; 2) the response of CAH-A to Tacrolimus treatment is rapid and sustained; and 3) a minor increase in the serum BUN and creatinine levels occurs as a consequence of Tacrolimus treatment. It is anticipated that with continued treatment for periods of 1–2 yr, the natural history of CAH-A will be changed such that hepatic failure and the requirement for liver transplantation may be averted.

### INTRODUCTION

Autoimmune chronic active hepatitis (CAH-A) is a chronic disorder of the liver characterized by hepatocellular injury and the development of a mixed macro-micronodular cirrhosis associated with the presence of a variety of autoimmune serological markers, including any combination of the following: antinuclear antibody (ANA), anti-smooth muscle (ASM), anti-thyroglobulin (AT) and liver or kidney microsomal (LKM) autoantibodies, a polyclonal gammopathy, human histocompatibility leukocyte antigens (HLA) and antigens B8 and Dr3 (1–19). The disease can occur in individuals of either gender but is four times more common in women than in men and can clinically present either as a chronic hepatitis with or without cirrhosis in the teenage years or as an established cirrhosis in an adult patient (1–6).

The specific etiology of CAH-A is unknown, but its association with HLA antigens B8 and Dr3 and a panoply of autoantibodies suggest that it is a consequence of an abnormal immune response directed at liver cells in response to a common viral agent or other environmental factor (9–21). Because of its presumed autoimmune etiology, a variety of immunosuppressive agents have been used in its clinical management (22–32). These include glucocorticoids, methotrexate, azathioprine, cyclophosphamide, d-penicillamine,

TABLE I  
*Demographic Data on the Subjects Studied*

Parameter	Result
Gender (Male/Female)	17/4
Age (Years)	42.3 ± 3.7
Duration of disease (Years)	4.2 ± 0.7
CAH alone at entry	52%
CAH + cirrhosis at entry	48%
Liver volume (cc)	1335 ± 119
HLA B8 positive	50%
HLA Dr3 positive	50%
HLA DrBW52 positive	72%
ANA positive	100%
Anti-smooth muscle positive	35%
Anti LKM positive	50%

TABLE 2  
Initial Clinical Characteristics of the Patients Studied

Parameter	Result	Normal
Total Bilirubin (mg/dl)	2.0 ± 0.7	<1.2
AST (IU/l)	224 ± 97	<32
ALT (IU/l)	248 ± 81	<32
Alkaline Phosphatase (U/l)	210 ± 41	<125
WBC (× 10 <sup>3</sup> )	5.1 ± 0.8	5-10
Platelet (× 10 <sup>3</sup> )	185 ± 49	150-300
BUN (mg/dl)	12.6 ± 1.9	5-20
Creatinine (mg/dl)	0.9 ± 0.1	<1.2

cyclosporin A, and, in the present preliminary report, Tacrolimus (FK 506). The use of Tacrolimus for patients with CAH-A has not been reported previously.

## METHODS

### Subjects

A total of 21 subjects with a histological and serologically confirmed diagnosis of CAH-A were studied. Each subject had a liver biopsy consistent with the diagnosis (7, 8) and had one or more autoantibodies known to be associated with

CAH-A. In addition, five were HLA B8-positive, and six were Dr3-positive. All subjects gave their informed, written consent for their participation in this study. Moreover, this study was approved by the committee evaluating human studies at the University of Pittsburgh before its initiation.

### Pretherapy evaluation

Each subject underwent a thorough pretherapy evaluation that included the following studies:

- 1 Complete blood count with platelet count;
- 2 A panel of liver injury and function parameters to include total bilirubin, ALT, AST, alkaline phosphatase (alk phos),  $\gamma$  glutamyl transpeptidase (GGPT), a serum electrophoresis, and a prothrombin time;
- 3 A percutaneous liver biopsy for histological evaluation and quantitation of the hepatic iron and copper content;
- 4 A CT scan of the liver for determination of liver volume;
- 5 An ultrasound examination of the liver to determine the status of the liver, biliary tree, and portal and hepatic vessels;
- 6 A panel of autoantibodies to include ANA, ASM, AT, and LKM.




FIG. 1. Serum ALT and AST levels at entry and 3-month intervals after starting Tacrolimus therapy. The points represent mean values; the brackets represent the SEM.




FIG. 2. Serum bilirubin and alkaline phosphatase levels at entry and at 3-month intervals while on Tacrolimus. The points represent mean values; the brackets represent the SEM.

#### Patient monitoring

After the pretherapy evaluation procedures were completed, each subject was given Tacrolimus at a starting dose of 0.075 mg/kg taken orally as equally divided doses 12 h apart. The initial dose was increased or reduced at 2-wk intervals to achieve a trough serum Tacrolimus level of 0.6–1.0 ng/ml. All Tacrolimus serum levels were obtained after an overnight fast and before the next morning's dose (33). Initially, all subjects were seen weekly (approximately 4 visits), then bi-weekly (2–3 visits), then monthly (2–3 visits), and finally, quarterly, until a 1-yr study period was completed.

At each visit, the following studies were obtained: 1) Complete blood count with platelet count; 2) Electrolytes, BUN, creatinine, blood sugar; 3) A liver injury panel consisting of the serum bilirubin, ALT, AST, alk phos, and  $\gamma$ GTP levels; 4) A serum tacrolimus level. At the end of a full year on the drug, all of the studies performed as part of the prestudy evaluation were repeated. All liver biopsies were read by staff pathologists at the University of Pittsburgh who were blinded to the nature of this study and the timing of the biopsies.

#### Statistical analysis

All results are presented as mean value  $\pm$  SEM. All data were compared using the entry and exit measures. The Student's one-tailed *t* test was used for statistical analysis. A *p* value  $<0.05$  was considered significant.

## RESULTS

A total of 21 subjects were enrolled in the open-label preliminary study evaluating the efficacy and toxicity of Tacrolimus in the treatment of CAH-A. The demographic data available on these 21 patients are shown in Table 1. As expected, most patients were women. More than half had one or another marker of an abnormal immune response (autoantibody) and were positive for the HLA antigens B8, Dr3, and DrBW52. The clinical characteristics of these same patients are shown in Table 2. Most had clinical jaundice, and all had markedly elevated ALT and AST levels. The patients' hematological parameters and renal function measures were normal. The time to achieve a stable serum Tacrolimus level between 0.6 and 1.0 ng/ml and to maintain renal function at acceptable levels was  $3.0 \pm 0.5$  wk. The mean Tacrolimus dose prescribed on a daily basis at this plateau level was  $7.2 \pm 0.8$  mg/day, and the mean daily dose on a per kg basis was  $0.06 \pm 0.01$  mg/kg/day.

As a result of the Tacrolimus treatment, the ALT and AST levels fell dramatically, as shown in Figure 1. Similarly, the serum total bilirubin level declined to a normal value (Fig. 2). The alkaline phosphatase level declined also but to a lesser degree and less consistently, probably because of the high rate of established cirrhosis in the populations studied (Fig. 2 and Table 1). The changes in the




FIG. 3. White blood cell and platelet counts in patients with CAH-A while receiving Tacrolimus. The *points* represent mean values; the *brackets* represent the SEM.

white blood cell counts and the platelet counts observed with Tacrolimus therapy are shown in Figure 3. The minor increase in BUN and creatinine observed with Tacrolimus therapy is shown in Figure 4.

#### DISCUSSION

CAH-A is a chronic hepatitis characterized histologically as showing piecemeal necrosis with a mononuclear infiltrate that consists predominantly of plasma cells and lymphocytes (1-8). Pathophysiologically, the disease is thought to represent an example of antibody-dependant cellular cytotoxicity mediated predominantly by natural killer cells (34-40). Individuals with this disease are thought to have an underlying genetic defect that makes them susceptible to an abnormal immune response to an environmental agent, either a virus (measles, cytomegalo virus or other) and to develop antibodies directed at a cross-reacting antigen or liver cells that enable natural killer cells to attack and kill antibody-coated hepatocytes (9-21).

In most studies, the serum AST and the degree of histological activity have been shown to be related (7, 8). This relationship between the serum AST level and the severity of the histological disease process is most apparent early in the dis-

ease course and is less strong as the disease progresses to cirrhosis and, ultimately, decompensated cirrhosis. Moreover, the histological disease is the parameter of disease severity that requires the longest time to correct with therapy, occurring weeks to months after clinical and biochemical resolution of disease (22, 30). Even with excellent clinical (subjective) and biochemical evidence for disease remission, half of the patients, when biopsied after 2 yr of glucocorticoid therapy either alone or in combination with azathioprine, will show continued disease activity. These latter patients are generally continued on immunosuppressive therapy lifelong (41-44).

Because of concerns about lifelong treatment of patients, the majority of whom are women and are, as a result, susceptible to enhanced rates of osteoporosis with glucocorticoids, some patients with CAH-A have been treated with cyclosporine A (CyA) (31). This latter agent is a more specific T cell specific immunosuppressive agent and has been used because of its powerful inhibitory effects on CD4<sup>+</sup> lymphocytes. Specifically, CyA reduces interleukin-2 (IL-2) production and IL-2 receptor expression on T lymphocytes and powerfully suppresses overall immune reactivity, presumably including that due to antibody-dependent cellular cytotoxicity, which is thought to be the mechanism responsible for liver cell injury




FIG. 4. Serum creatinine and BUN levels in the patients treated with Tacrolimus for CAH-A. The dose and blood level of Tacrolimus achieved is also shown. The points represent mean values; the brackets represent the SEM.

and death in CAH-A. Preliminary trials with CyA have been promising but have been limited by the nephrotoxicity associated with its use (31).

Tacrolimus is a new macrolide antibiotic with immunosuppressive activity that is reported to be 100–1000 times more powerful on a molecular basis than CyA when treated in various *in vitro* assay systems (45). Clinically, Tacrolimus has been shown to be useful in organ allograft recipients when CyA either has not worked or its use has been limited by nephrotoxicity or some other manifestation of drug toxicity, such as hypertension or neurotoxicity (46–53).

The present study was initiated to determine whether or not Tacrolimus could be used in cases of CAH-A to obtain control of the disease process and if so, at what cost in terms of its nephrotoxicity, neurotoxicity, and diabetogenic activity? As is readily apparent from the data presented in Figures 1–4, Tacrolimus can be used effectively to treat CAH-A. Moreover, the cost of such treatment in terms of the nephrotoxicity of chronic Tacrolimus administration at the doses and levels used in this study are not particularly severe (Fig. 4) and therefore not limiting. Specifically, a

greater than 75% reduction in ongoing hepatic injury as manifested by the serum levels of AST and ALT was noted with Tacrolimus therapy (Fig. 1). Moreover, a substantial improvement in hepatic function, as manifested by the decline to normal of the serum bilirubin level, was observed with continued Tacrolimus treatment (Fig. 2).

The change in renal function observed as a result of Tacrolimus treatment was minor and at no time limited therapy (Fig. 4).

These results suggest that Tacrolimus should be used in a randomized control study against prednisone to define its clinical efficacy against the best available current therapy.

Reprint requests and correspondence: David H. Van Thiel, M.D., Oklahoma Transplant Institute, Baptist Medical Center of Oklahoma, 3300 Northwest Expressway, Oklahoma City, OK 73112

#### REFERENCES

1. Kunkel HG, Abrens EH Jr, Eisenmenger WJ. Extreme hypergammaglobulinemia in young women with liver disease of unknown etiology. *J Clin Invest* 1951;30:654–9

2. Wilcox RG, Isselbacher KJ. Chronic liver disease in young people. Clinical features and course of 33 patients. *Am J Med* 1961;30:185-95.
3. Mackay IR. Autoimmune hepatitis: An etiology in the spectrum of chronic active liver disease. *J Gastroenterol Hepatol* 1990;5:352-7.
4. Hodges JR, Millward-Sadler GH, Wright R. Chronic active hepatitis: The spectrum of disease. *Lancet* 1982;1:550-2.
5. Keating JJ, O'Brien CJ, Stellon AJ, et al. Influence of aetiology, clinical and histological features on survival in chronic active hepatitis: An analysis of 204 patients. *Q J Med* 1987;62:59-66.
6. Galbraith RM, Smith M, Mackenzie RM, Tee DE, Doniach D, Williams R. High prevalence of seroimmunologic abnormalities in relatives of patients with active chronic hepatitis or primary biliary cirrhosis. *N Engl J Med* 1974;290:63-9.
7. Baggenstoss AH, Soloway RD, Summerskill WHJ. Chronic active liver disease: The range of histologic lesions, their responses to treatment and evolution. *Hum Pathol* 1972;3:183-98.
8. Dienes HP, Popper H, Manns M. Histologic features in autoimmune hepatitis. *Z Gastroenterology* 1989;27:325-30.
9. Mackay IR, Morris PJ. Association of autoimmune active chronic hepatitis with HLA-A1.8. *Lancet* 1972;2:793-5.
10. Whittingham S, Mathews JD, Schanfield MS, Tait BD, Mackay IR. Interaction of HLA and Gm in autoimmune chronic active hepatitis. *Clin Exp Immunol* 1981;43:80-6.
11. Nouri-Aria KT, Donaldson PT, Hegarty JE, Eddleston ALWF, Williams R. HLA A1-B8-DR3 and suppressor cell function in first degree relatives of patients with autoimmune chronic active hepatitis. *J Hepatol* 1985; 1:235-41.
12. Krawitt EL, Kilby AE, Albertini RJ. Immunogenetic studies of autoimmune chronic active hepatitis. HLA, immunoglobulin allotypes and autoantibodies. *Hepatology* 1987;7:1305-10.
13. Johnson PJ, Macfarlane IG, McFarlane BM, Williams R. Autoimmune features in patients with idiopathic chronic active hepatitis who are seronegative for conventional autoantibodies. *J Gastroenterol Hepatol* 1990;5:244-51.
14. Gurian LE, Regoff TM, Ware AJ. The immunologic diagnosis of chronic autoimmune hepatitis: distinction from systemic lupus erythematosus. *Hepatology* 1985;5:397-402.
15. Wood JR, Czaja AF, Beaver SJ. Frequency and significance of antibody to double stranded DNA in chronic active hepatitis. *Hepatology* 1986;6:976-80.
16. Homberg J-C, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with anti-liver/kidney microsome antibody type 1: A second type of "autoimmune" hepatitis. *Hepatology* 1987;7:1333-9.
17. Manns MP, Johnson EF, Griffin KJ. The major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome p450 dbl. *J Clin Invest* 1989;83:1066-72.
18. Treichel U, Panalla T, Hess G. Autoantibodies to human asialoglycoprotein receptor in autoimmune-type chronic hepatitis. *Hepatology* 1990;11:606-12.
19. Wachter B, Kyriatsoulis A, Lohse AW. Characterization of liver cytotokeratin as a major antigen of anti HLA antibodies. *J Hepatology* 1990;11:232-9.
20. Robertson DAF, Zhang SL, Guy EC, Wright R. Persistent measles virus genome in autoimmune chronic active hepatitis. *Lancet* 1987;1: 9-11.
21. Christie KE, Haukenes G. Measles virus specific precipitins in sera from patients with chronic active hepatitis. *Scand J Infect Dis* 1979; 11:99-106.
22. Read AE, Sherlock S, Harrison CV. Active "juvenile" cirrhosis considered as part of a systemic disease and the effect of corticosteroid therapy. *Gut* 1963;4:378-93.
23. Copenhagen Study Group for Liver Disease. Effect of prednisone on the survival of patients with cirrhosis of the liver. *Lancet* 1969;1:119-21.
24. Cook GL, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. *Q J Med* 1971;40: 159-85.
25. Soloway RD, Summerskill WHJ, Baggenstoss A. Clinical biochemical and histological remission in severe chronic active liver disease: A controlled study of treatment and early prognosis. *Gastroenterology* 1972;63:820-33.
26. Murray Lyon IM, Stern RB, Williams R. Controlled trial of prednisolone and azathioprine in active chronic hepatitis. *Lancet* 1973;2: 735-7.
27. Kirk AP, Jain S, Pocock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. *Gut* 1980;21:78-83.
28. Czaja AJ, Davis GL, Ludwig J. Autoimmune features as determinants of prognosis in steroid chronic active hepatitis of uncertain etiology. *Gastroenterology* 1983;85:713-7.
29. Davis GL, Czaja AL, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid treated hepatitis B surface antigen negative chronic active hepatitis. *Gastroenterology* 1984;87:1222-7.
30. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg negative chronic active hepatitis. *Hepatology* 1984;4:622-7.
31. Mistilis SP, Vickers CR, Darroch MH, McCarthy SW. Cyclosporin, a new treatment for autoimmune chronic active hepatitis. *Med J Austr* 1985;143:463-5.
32. Mistilis SP, Blackburn CRB. The treatment of active chronic hepatitis with 6-mercaptopurine and azathioprine. *Austr Ann Med* 1967;16: 305-11.
33. Kobayashi M, Tamura K, Katayama N, et al. FK 506 assay past and present. Characteristics of FK 506 ELISA. *Transplant Proc* 1991;23: 2725-9.
34. Mondelli M, Eddleston ALWF. Lymphocyte cytotoxicity for autologous hepatocytes. *Gut* 1984;25:109-13.
35. Manns MP, Nakamura RM. Autoimmune liver disease. *Clin Lab Med* 1988;8:281-301.
36. Wen L, Peakman M, Lobo-Yeo A. Evidence that circulating activated T cell lymphocytes direct the immune attack on the liver cells in autoimmune chronic active hepatitis. *Lancet* 1990;330:1527-30.
37. Vento S, Eddleston ALWF. Immunological aspects of chronic active hepatitis. *Clin Exp Immunol* 1987;68:225-32.
38. Vergani GM, Vergani D, Jenkins PJ, et al. Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg negative chronic active hepatitis. *Clin Exp Immunol* 1979;38:16-21.
39. Eggink HF, Howthoff HJ, Huitema S. Cellular and humeral reactions in chronic active liver disease. I. *Clin Exp Immunol* 1982;50:17-24.
40. Poralla T, Ramadori G, Dienes HP. Liver cell damage caused by monoclonal antibody against an organ specific membrane antigen in vivo and in vitro. *J Hepatology* 1987;4:373-80.
41. Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A. Corticosteroid-treated chronic active hepatitis in remission. *N Engl J Med* 1981;304:5-9.
42. Hegarty JE, Nouri Aria KT, Portmann B, Eddleston ALWF, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. *Hepatology* 1983;3:685-9.
43. de Groote J, Fevery J, Lepoutre L. Long-term follow-up of chronic active hepatitis of moderate severity. *Gut* 1978;19:510-3.
44. Schalm SW, Ammon HV, Summerskill WHJ. Failure of customary treatment in chronic active liver disease: Causes and management. *Ann Clin Res* 1976;8:221-7.
45. Kobayashi M, Tamura K, Katayama N, et al. FK 506 assay past and present: Characteristics of FK 506 ELISA. *Transplant Proc* 1991;23: 2725-9.
46. Fung J, Abu-Elmagd K, Jain A, et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. *Transplant Proc* 1991;23:2977-83.
47. Winkler M, Ringe B, Gerstenkorn C, Rodeck B, Gubernatis G, Woniheit K, et al. Use of FK 506 for treatment of chronic rejection after liver transplantation. *Transplant Proc* 1991;23:2984-6.
48. D'Alessandro AM, Kalayoglu M, Pirsch JD, et al. FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients. *Transplant Proc* 1991;23:2987-8.
49. Shaw BW Jr, Markin R, Stratta R, Langnas A, Donovan J, Sorrell M. FK 506 rescue treatment of acute and chronic rejection in liver allograft recipients. *Transplant Proc* 1991;23:2994-5.
50. McDiarmid SV, Klintmalm G, Busutil RW. FK 506 rescue therapy in liver transplantation: Outcome and complications. *Transplant Proc* 1991;23:2996-9.
51. Demetris AJ, Fung JJ, Todo S, et al. FK 506 used as rescue therapy for human liver allograft recipients. *Transplant Proc* 1991;23:3005-6.
52. Miele LA, Fung JJ, Yokoyama I, et al. Liver transplantation of American veterans under FK 506 immunosuppression: A preliminary report. *Transplant Proc* 1991;23:3016-8.
53. Takaya S, Bronshter O, Todo S, et al. Retransplantation of liver: A comparison of FK 506- and cyclosporine-treated patients. *Transplant Proc* 1991;23:3026-8.